New York Attorney General Letitia James has announced a settlement with eight pharmaceutical companies, resulting in approximately $720 million to address the opioid crisis. The funds aim to provide essential resources for communities across New York and the nation. Of this amount, New York will receive up to $38.7 million. Attorney General James has now secured over $3 billion for opioid abatement, treatment, and prevention efforts in New York.
Attorney General James stated, “For years, drug companies prioritized profits at the expense of struggling New Yorkers who became trapped in deadly opioid addictions.” She emphasized that these resources would aid in healing affected communities and reiterated her commitment to holding accountable those responsible for the crisis.
The eight companies involved are Mylan (now part of Viatris), Hikma, Amneal, Apotex, Indivior, Sun, Alvogen, and Zydus. Their payments range from a single year to over a decade starting as soon as 2026. Additionally, they will contribute $14 million more and provide medications or cash equivalent valued at about $86 million. Most of these companies will face restrictions on promoting opioids or selling high-dose oxycodone products.
In New York, Special Counsel Monica Hanna and Assistant Attorney General Matthew Conrad led the settlement negotiations with assistance from Deputy Director Gautam Sisodia and Data Scientist Kenneth Morales under First Deputy Attorney General Jennifer Levy’s supervision. Other states involved include California, Colorado, Illinois, North Carolina, Oregon, Tennessee, Utah, and Virginia.
Attorney General James is recognized nationally for her role in securing funds from various companies linked to the opioid epidemic. Her efforts have brought over $3 billion into New York’s initiatives against addiction through settlements with several major corporations including Purdue Pharma and Johnson & Johnson among others.
